PLA2G7 and coronary artery disorder: Conversely, based on current evidence, broad-spectrum immunomodulators (e.g., methotrexate) and downstream inhibitors (e.g., Lp-PLA2 inhibitors, p38 MAPK inhibitors) should not be used in CHD patients, as they have not demonstrated significant benefit.